FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2648-2650 June 23, 2005 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Drazen, J. M. Related Article by Psaty, B. M. Related Article by Solomon, S. D. PubMed Citation

To the Editor: Solomon et al., for the Adenoma Prevention with Celecoxib (APC) Study Investigators (March 17 issue),¹ reported an increase in cardiovascular events associated with the use of celecoxib, and two accompanying editorials^2,3 supported the conclusion of a class effect for cyclooxygenase-2 (COX-2) inhibitors. Although abundant and concordant data from both randomized trials and observational studies show that the use of rofecoxib is associated with cardiovascular risk, the literature concerning the risk with the use of celecoxib is more heterogeneous. Numerous observational studies^4,5,6,7,8 have failed to identify an increased risk with celecoxib. Moreover, among randomized trials of celecoxib with . . . [Full Text of this Article]

This article has been cited by other articles:

• Stafford-Smith, M. (2006). Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2.. Canadian J. Anesthesia 53: 973-977 [Full Text]  
• Levesque, L. E., Brophy, J. M., Zhang, B. (2006). Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174: 1563-1569 [Abstract] [Full Text]